Systems‐based digital twins to help characterize clinical <scp>dose–response</scp> and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in <scp>NHL</scp>
Monica Susilo, Iraj Hosseini, Jin Y. Jin(Jiangxi Normal University), Michael C. Wei(The Royal Melbourne Hospital), Genevive Hernandez(Sutro Biopharma (United States)), Kapil Gadkar(Sea Turtle Conservancy), Chi‐Chung Li, Saroja Ramanujan(Unknown), Ling‐Yuh Huw, Shen Yin
Cited by 74
Related Papers
tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c
|Genes & Development|2000|1.3k
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
|The Lancet Oncology|2022|429
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
|Science Translational Medicine|2014|373
A Comprehensive Review of Interventions in the NOD Mouse and Implications for Translation
|Immunity|2005|317
Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
|Science Translational Medicine|2013|267